FDA-Approved Epilepsy Drug May Help Reverse Osteoarthritis Damage
New research from Yale shows that lacosamide, an FDA-approved epilepsy drug, can reduce joint pain and reverse cartilage damage in osteoarthritis. The drug is most effective when delivered directly into the joint using a specialized hydrogel.
What Happened?
New research from Yale shows that lacosamide, an FDA-approved epilepsy drug, can reduce joint pain and reverse cartilage damage in osteoarthritis. The drug is most effective when delivered directly into the joint using a specialized hydrogel.
AI Quick Summary
Yale researchers found that lacosamide, an epilepsy drug, can reduce osteoarthritis pain and repair cartilage when injected directly into the joint.
Key points
- Lacosamide can reduce joint pain and reverse cartilage damage.
- The drug is most effective when injected directly into the joint.
- Nav1.7 protein plays a role in pain signaling and cartilage breakdown.
- Lacosamide encourages cartilage-building proteins at optimal low concentrations.
- A specialized hydrogel keeps the drug localized in the joint.
Key insights
- If successful, this approach could reduce the need for joint surgeries.
- Using existing medications like lacosamide may speed up clinical trials.
- The hydrogel delivery system could enhance treatment effectiveness.
- Targeting Nav1.7 may provide a dual benefit of pain relief and cartilage preservation.
Why it matters
This research could lead to new treatments that not only relieve pain but also modify the progression of osteoarthritis.
Tags
Entities
Source
Science Daily